Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration

Gavin R Meehan, Hannah E Scales, Iain B McInnes, James M Brewer and Paul Garside*

School of Infection and Immunity, University of Glasgow, Glasgow, UK
*Correspondence: Paul Garside, School of Infection and Immunity College of Medical, Veterinary & Life Sciences Sir Graeme Davies Building University of Glasgow 120 University Place, Glasgow G12 8TA, UK. Email: paul.garside@glasgow.ac.uk

Summary
Currently, treatments for rheumatoid arthritis (RA) are focussed on management of disease symptoms rather than addressing the cause of disease, which could lead to remission and cure. Central to disease development is the induction of autoimmunity through a breach of self-tolerance. Developing approaches to re-establish antigen specific tolerance is therefore an important emerging area of RA research. A crucial step in this research is to employ appropriate animal models to test prospective antigen specific immunotherapies. In this short communication, we evaluate our previously developed model of antigen specific inflammatory arthritis in which ovalbumin-specific T cell receptor transgenic T cells drive breach of tolerance to endogenous antigens to determine the impact that the timing of therapy administration has upon disease progression. Using antigen feeding to induce tolerance we demonstrate that administration prior to articular challenge results in a reduced disease score as evidenced by pathology and serum antibody responses. By contrast, feeding antigen after initiation of disease had the opposite effect and resulted in the exacerbation of pathology. These preliminary data suggest that the timing of antigen administration may be key to the success of tolerogenic immunotherapies. This has important implications for the timing of potential tolerogenic therapies in patients.

Graphical Abstract

Keywords: arthritis, tolerance, antigen feeding, ovalbumin, immunotherapy

Abbreviations: RA: Rheumatoid arthritis; TCR: T cell receptor; tolDCs: Tolerogenic dendritic cells; OVA: Ovalbumin; Treg: Regulatory T cell; CII: Type II collagen; CFA: Freund's complete adjuvant; IFA: Freund's incomplete adjuvant; HAO: Heat aggregated ovalbumin.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory condition in which a series of genetic and environmental factors trigger a breach of immunological self-tolerance. This results in the development of autoimmunity and ultimately culminates in the destruction of the bone and cartilage of the joints. Current therapies for the treatment of RA focus on decreasing joint inflammation and preventing disease progression but do not treat the underlying cause of pathology. Consequently, there has been an increasing drive to focus research on the development of antigen-specific immunotherapies that would restore immunological homeostasis and allow for drug-free remission [1].

Tolerogenic therapies can take many forms including tolerogenic dendritic cells (tolDCs), regulatory T cell (Treg) induction, tolerogenic liposomes, and antigen feeding [2]. Various pre-clinical models have examined these therapies and a number are undergoing clinical trials for the treatments of other autoimmune diseases [3–5]. However, questions remain regarding the form these therapies should take and how they should be administered. In particular, the timing of administration may be key to ensuring that the therapies are not only successful but do not exacerbate the disease. Thus, will tolerogenic therapies require administration in at-risk patients prior to overt pathology or will they be effective in the latter scenario?

To examine the impact of timing on antigen-specific immunotherapy administration we employed ovalbumin (OVA) induced model of antigen-specific inflammatory arthritis, in which OVA-specific TCR tg T cells drive breach of tolerance to endogenous antigens. Using this model, we fed mice OVA protein at various stages of the disease to determine the impact of antigen feeding on pathology and whether tolerance could be induced.

Materials and methods
Animals
C57BL/6J mice were purchased from Envigo (Wyton, UK). CD45.1+ OTII mice were produced in-house (Central Research Facility, University of Glasgow, UK). Animals were maintained on a 12-hour light/dark cycle and provided with food and water ad libitum. Due to the long-term nature of these experiments, female mice were used to reduce fighting between cage mates; however, both sexes have been used with this model in the past. All procedures were performed under a UK Home Office licence in accordance with the Animals (Scientific Procedures) Act 1986.

Induction of OVA breach of tolerance arthritis model
The OVA breach of tolerance arthritis model was used as described previously [6, 7] with modifications in timings made to accommodate antigen feeding. Briefly, OVA-specific T cell receptor (TCR) transgenic CD4 T cells were isolated from the lymph nodes and spleens of 6- to 12-week-old female OTII mice. Th1 cell differentiation was induced by culturing CD4 T cells with antigen-presenting cells treated with 50 µg/ml mitomycin C (Merck, Darmstadt, Germany) in the presence of 1 µg/ml OVA [123–339] (Peprotech, Rocky Hill, NJ, USA), 10 ng/ml IL-12 (R&D systems, Minneapolis, MN, USA), and 2 µg/ml anti-IL4 (Biolegend, San Diego, CA, USA) for 3 days. The purity of the OTII cells was confirmed by flow cytometry and 3,000,000 cells were injected intravenously into recipient C57BL/6J mice. The number of cells used for adoptive transfer is routinely used within our lab [8], with previous pilot studies indicating inefficient retention of higher cell numbers. The purity of Th1-polarised OTII cells was always >90%. The following day mice were injected subcutaneously with 100 µl of 100 µg grade V OVA emulsified in Freund’s complete adjuvant (CEA) (Sigma Aldrich, St Louis, MO, USA). Twenty-one days later, the mice were challenged with a periarticular injection of 50 µl PBS containing 100 µg heat aggregated grade V OVA (HAO) into a hindlimb. HAO was prepared by heating OVA in PBS at 100°C for 2 hours and was used to prevent drainage of the antigen from the injection site. Rechallenges, when performed, consisted of an articular injection of 50 µl Freund’s incomplete adjuvant (IFA) (Sigma Aldrich, St Louis, MO, USA) containing 100 µg grade V OVA given 63 days after the first HAO challenge. Mice were weighed and monitored daily for signs of arthritis. Each footpad was measured using digital callipers and given a disease score based upon erythema, swelling, and loss of function as described previously [6].

Antigen feeding
Grade V OVA protein (Sigma Aldrich, St Louis, MO, USA) was prepared in sterile water at 40 mg/ml and gently agitated at 4°C overnight. The dissolved OVA was filtered through a 0.22 µM membrane and added to sterile water bottles in the treatment groups cages for 10 days. The water bottles were changed daily. Control mice received sterile tap water. The timing of antigen feeding is indicated in each experiment.

Histology
Histology was performed as described previously [9]. Briefly, hind limbs were collected and stored in 10% neutral buffered formalin. The tissue was then decalcified in 5% formic acid and processed for wax embedding. Tissue sections (8 µm) were cut along the sagittal plane and stained with haematoxylin and eosin or toluidine blue. Images were taken using an EVOS Cell Imaging System (Thermofisher, Waltham, MA, USA). Scoring was performed by a blinded observer based on a scale of 0–3 for cellular infiltration, synovial hyperplasia, and cartilage/bone erosion as described previously [6]. In addition, mice were given a score of 0 or 1 based on the presence of ulceration. This provided each mouse with a total score out of 10.

Serum antibody ELISA
The levels of serum anti-OVA or anti-collagen type II (CII) IgG1 and IgG2c were measured using enzyme-linked immunosorbent assays (ELISA) as described previously [6]. Briefly, ELISA plates (Corning Inc, Corning, NY, USA) were coated with 20 µg/ml OVA protein (Sigma Aldrich, St Louis, MO, USA) or 4 µg/ml CII (Sigma Aldrich, St Louis, MO, USA) in sodium bicarbonate buffer (Sigma Aldrich, St Louis, MO, USA) overnight at 4°C. Plates were washed in PBS-Tween (PBS-T) and blocked in animal-free block (Vector Laboratories, Burlingame, CA, USA) for 1 hour at 4°C. Serum samples were prepared at 1:50 and serially diluted across the ELISA plate. The samples were incubated overnight at 4°C. The plates were then washed in PBS-T. Biotin anti-mouse IgG1 or IgG2C (Jackson Laboratory, Bar Harbor, ME, USA)
were prepared in PBS at 1:5000 and 1:2000 dilutions, respectively, and added for 1 hour at 4°C. The plates were washed again in PBS-T and incubated with ExtrAvidin peroxidase (Sigma Aldrich, St Louis, MO, USA) at a 1:10,000 dilution for 1 hour at 4°C. The plates were washed in PBS-T and developed using SIGMAFAST OPD tablets (Sigma Aldrich, St Louis, MO, USA) in the dark at room temperature for 20 minutes. The plates were stopped with the addition of 50 μl of 10% sulphuric acid and then read at 492 nm using a Tecan ELISA plate reader (Tecan Group, Männedorf Switzerland).

Statistical analysis
All graphs and statistical analyses were produced using GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA, USA). P values < 0.05 were deemed to be significant.

Results and discussion
To determine whether feeding antigen could induce tolerance we used the OVA breach of tolerance model of inflammatory arthritis. In this model, Th1 polarised OVA-specific TCR transgenic T cells are adaptively transferred into mice, which are subsequently immunised with OVA/CFA and then given an articular challenge with HAO [6]. The resultant inflammatory response triggers a breach of tolerance to endogenous antigens. We fed OVA to mice either pre- or post-immunisation with OVA/CFA or post-articular challenge with HAO (Fig 1a). Feeding OVA before OVA/CFA immunisation resulted in a significant reduction in footpad swelling 24 hours post-HAO challenge (two-way ANOVA, **<0.01) (Fig 1b). Although previous studies have shown that feeding soluble type II collagen before the induction of collagen-induced arthritis (CIA) produces less severe disease [10, 11], the observation of this effect in a model with antigen-stimulated Th1-polarised T cells indicates the effectiveness of antigen feeding in promoting tolerance at this stage of the disease.

A similar effect was observed following OVA feeding after immunisation with OVA/CFA (Fig 1c). Footpad swelling was significantly reduced in both 24 hours (two-way ANOVA, *<0.05, ***<0.001) and 48 hours (two-way ANOVA, *<0.05) post-HAO challenge. This was accompanied by a significant reduction in anti-OVA IgG1 (two-way ANOVA, **<0.01) (Fig 1d) and IgG2C (two-way ANOVA, *<0.05) (Fig 1e) antibodies in the OVA-fed group. Similarly, anti-collagen II (CII) antibodies that were tracked for several weeks post-HAO challenge were consistently lower in the OVA-fed group although there was only a significant difference at week 5 (two-way ANOVA, **<0.01) (Fig 1f). The histology score, based upon cellular infiltration, synovial hyperplasia, and cartilage/bone erosion, was also significantly reduced in this group (Mann–Whitney test) (Fig 2f). We hypothesise that the severity of the inflammation in both treatment groups may have obscured our ability to distinguish subtle differences between them. One notable difference was the presence of substantial ulceration in the footpads of the OVA-fed/rechallenged mice (Fig 2g). The presence of ulceration suggests a more severe inflammatory response in these mice. This could be due to the antigen-feeding expanding effector T cells or the absence or loss of Treg suppression. We speculate that antigen feeding after the HAO challenge may prevent the regulation of the OTII T cells, which drives autoreactivity but a detailed immunological analysis, including T cell phenotyping and cytokine profiling, would need to be performed to assess this further. In addition, further independent repeats of these experiments should be performed to validate these results although the control groups in these studies behaved as we have described previously [13, 14].

One aspect that would be interesting to examine within this model would be the effect of antigen dose. Previous work has demonstrated that the mechanism of tolerance varies with the amount of antigen fed, with high doses inducing clonal deletion or anergy [15] while lower doses promote Treg induction [16]. As these different mechanisms might impact the effectiveness and duration of tolerance, they would be worth further examination in future studies.

Taken together, these data suggest that earlier interventions with tolerogenic therapies are likely to be key to their success. Many previous animal studies in both immunisation [17, 18] and disease models [19, 20] have demonstrated that it is relatively easy to induce tolerance prophylactically whereas it is much more challenging to tolerate an already primed immune response during active disease. Critically, studies in a murine model of autoimmune diabetes found an exacerbation
of pathology when attempting to tolerise a primed immune response [21].

Although it is unclear if these results translate into human disease, they suggest that tolerogenic therapies would be best targeted at individuals at risk of developing or in the very early stages of RA. In contrast, attempting to tolerise individuals in the clinical phase of RA may result in an exacerbation of symptoms and a poorer outcome. In addition, we have recently demonstrated in our animal model that the repertoire of antigens to which tolerance is breached becomes wider at later time points following an initial breach of tolerance providing another reason to target therapy early [14].

Although the disease-inducing antigen is currently unknown in RA, our model provides a basis for understanding how tolerance can be re-established following the initiation of the disease. An important feature of the model is that administration of the disease-eliciting antigen (OVA) leads to a breach of tolerance to self-antigens. This includes responses to collagen and a variety of citrullinated peptides which are associated with joint pathology in other models and patients. Further work should be performed to determine whether antigen feeding can induce tolerance in drug-controlled clinical phase arthritis and whether the effectiveness of other tolerogenic therapies is also dependent upon administration at a specific phase of the disease.
Acknowledgements

We acknowledge the assistance of the Histology Research Service at the University of Glasgow. We also acknowledge Dr. Robert Benson and Veronica Patton at the University of Glasgow for their assistance in scoring histology sections. The Editor-in-Chief, Tim Elliot, and handling editor, Menno van Zelm, would like to thank the following reviewers, Martijn van Herwijnen and Graham Anderson, for their contribution to the publication of this article.

Author Contributions

GRM designed the research, performed the experiments, constructed the figures, analysed the data, and wrote the manuscript. HES assisted with experiments and edited the manuscript. IBM, JMB, and JMB designed the research and contributed to writing the article.

Permission to Reproduce

This work may be reproduced with the permission of the corresponding author.

Clinical trial registration

N/A

Funding

This work was supported by funding from the Innovative Medicines Initiative 2 Joint Undertaking [Grant No 777357]. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. www.imi.europa.eu. HES was funded by the University of Glasgow.

Figure 2. Antigen feeding post-challenge exacerbates disease. (a) Following the induction of inflammatory arthritis, mice were fed ovalbumin following a challenge with heat aggregated ovalbumin (HAO). Control mice were not fed antigen. The mice were then rechallenged with OVA/IFA and footpad measurements (a) were taken 0, 24, 48, 72, and 96 hours post-rechallenge. n=5 from one independent experiment. Statistical analysis was performed using a two-way ANOVA, ns = no significance, **<0.01, ***<0.0001. (b) Representative photographs of the challenged footpads indicate differences in the disease states of the mice. ELISAs were performed on the serum of mice that had been fed ovalbumin post-immunisation. These examined anti-OVA IgG1 (c), anti-OVA IgG2C (d), and anti-CII IgG (e) antibodies. n = 5 from one independent experiment. Statistical analysis was performed using a two-way ANOVA, ***<0.001. Blue shaded boxes signify period of antigen feeding. Blue and red dashed lines signify HAO challenge and OVA rechallenge respectively. (f) Histology was performed on the joints of mice fed ovalbumin post-immunisation. n = 5 from one independent experiment. Disease scoring was performed blinded. Statistical analysis was performed using a Mann–Whitney test. (g) Histological images indicate the presence of ulceration in the footpads of the OVA-fed/rechallenged mice.
Competing Interests
The authors have no competing interests.

Arrive Guidelines
All animal research adhered to ARRIVE guidelines (https://arriveguidelines.org/arrive-guidelines).

Data Availability
Data is available to readers upon request from the corresponding author.

Statements Disclaimer
This communication reflects the authors’ views and neither the corresponding author.

References
This information contained within.

1. Albani S, Koffeman EC, Prakken B. Induction of immune tolerance in the treatment of rheumatoid arthritis. Nat Rev Rheumatol 2011; 7:272–81. https://doi.org/10.1038/nrrheum.2011.36
2. Meehan GR, Thomas R, Al Khabouri S et al. Preclinical models of arthritis for studying immunomodulation and immune tolerance. Ann Rheum Dis 2021; 80:1268–77. https://doi.org/10.1136/annrheumdis-2021-220043
3. Willekens B, Presas-Rodríguez S, Mansilla MJ et al. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open 2019; 9:e030309. https://doi.org/10.1116/bmjopen-2019-030309
4. Phillips BE, Garciafigueroa Y, Engman C et al. Tolerogenic dendritic cells and T-regulatory cells at the clinical trials crossroad for the treatment of autoimmune disease; emphasis on type 1 diabetes therapy. Front Immunol 2019; 10:148. https://doi.org/10.3389/fimmu.2019.00148
5. Pearce SHS, Dayan C, Wraith DC et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism: a phase I study. Thyroid 2019; 29:1003–11. https://doi.org/10.1089/thy.2019.0036
6. Maffia P, Brewer JM, Gracie JA et al. Inducing experimental arthritis and breaking self-tolerance to joint-specific antigens with trackable, ovalbumin-specific T cells. J Immunol 2004; 173:151–6. https://doi.org/10.4049/jimmunol.173.1.151
7. Prendergast CT, Patakas A, Al-Khabouri S et al. Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis. Ann Rheum Dis 2018; 77:579–88. https://doi.org/10.1136/annrheumdis-2017-212279
8. Benson RA, Macleod MKL, Hale BG et al. Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo. Elife 2015; 55:1–16.
9. Joosten LAB, Lubberts E, Durez P et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249–60. https://doi.org/10.1002/art.1780400202
10. Nagler-Anderson C, Bober LA, Robinson ME et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci 1986;83:7443 L–7446.
11. Thompson HS, Staines NA. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol 1986; 64:581–6.
12. Thomé R, Fernandes LGR, Mineiro MF et al. Oral tolerance and OVA-induced tolerogenic dendritic cells reduce the severity of collagen/ovalbumin-induced arthritis in mice. Cell Immunol 2012; 280:113–23. https://doi.org/10.1016/j.cellimm.2012.11.017
13. Coniglio P, Benson RA, Patakas A et al. Characterization of the antigenic collagen antibody response in a new model of chronic polyarthritis. Arthritis Rheum 2011; 63:2299–308. https://doi.org/10.1002/art.30413
14. Al Khabouri S, Benson RA, Prendergast CT et al. TCRβ Sequencing reveals spatial and temporal evolution of clonal CD4 T cell responses in a breach of tolerance model of inflammatory arthritis. Front Immunol 2021; 12:1399
15. Garside P, Steel M, Worthy EA et al. Lymphocytes from orally tolerized mice display enhanced susceptibility to death by apoptosis when cultured in the absence of antigen in vivo. Am J Pathol 1996; 149:1971–9.
16. Weiner HL, da Cunha AP, Quintana F et al. Oral tolerance. Immunol Rev 2011; 241:241–59. https://doi.org/10.1111/j.1600-065X.2011.01017.x
17. Leishman AJ, Garside P, Mowat AMI. Induction of oral tolerance in the primed immune system: influence of antigen persistence and adjuvant form. Cell Immunol 2000; 202:71–8. https://doi.org/10.1006/cimm.2000.1665
18. Leishman AJ, Garside P, Mowat AM. Immunological consequences of intervention in established immune responses by feeding protein antigens. Cell Immunol 1998; 183:137–48. https://doi.org/10.1006/cimm.1998.1242
19. Torseth JW, Gregerson DS. Oral tolerance in experimental autoimmun uveoretinitis: feeding after disease induction is less protective than prefeeding. Clin Immunol Immunopathol 1998; 88:297–304. https://doi.org/10.1006/clim.1998.4592
20. Weiner HL. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest 2000; 106:935–7. https://doi.org/10.1172/JCI11348
21. Efrofmssini B, Carbone FR, Allison J et al. Induction of autoimmune diabetes by oral administration of autoantigen. Science (80-) 1996; 274:1707–9.